PT2038252T - Acilanilidos substituidos e métodos de utilização dos mesmos - Google Patents
Acilanilidos substituidos e métodos de utilização dos mesmosInfo
- Publication number
- PT2038252T PT2038252T PT77968238T PT07796823T PT2038252T PT 2038252 T PT2038252 T PT 2038252T PT 77968238 T PT77968238 T PT 77968238T PT 07796823 T PT07796823 T PT 07796823T PT 2038252 T PT2038252 T PT 2038252T
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- substituted acylanilides
- acylanilides
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83015806P | 2006-07-12 | 2006-07-12 | |
US83966506P | 2006-08-24 | 2006-08-24 | |
US90774807P | 2007-04-16 | 2007-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2038252T true PT2038252T (pt) | 2016-12-16 |
Family
ID=38923890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT77968238T PT2038252T (pt) | 2006-07-12 | 2007-07-12 | Acilanilidos substituidos e métodos de utilização dos mesmos |
Country Status (20)
Country | Link |
---|---|
US (1) | US20080076828A1 (pt) |
EP (2) | EP3147278B1 (pt) |
JP (5) | JP5215300B2 (pt) |
KR (2) | KR101460999B1 (pt) |
CN (1) | CN101516840B (pt) |
AR (1) | AR061980A1 (pt) |
AU (1) | AU2007272950B2 (pt) |
BR (1) | BRPI0713179A2 (pt) |
CA (1) | CA2658394C (pt) |
CY (1) | CY1118472T1 (pt) |
DK (1) | DK2038252T3 (pt) |
EA (3) | EA018258B1 (pt) |
ES (2) | ES2606313T3 (pt) |
HU (1) | HUE032274T2 (pt) |
IL (3) | IL196462A (pt) |
LT (1) | LT2038252T (pt) |
MX (1) | MX2009000385A (pt) |
PL (1) | PL2038252T3 (pt) |
PT (1) | PT2038252T (pt) |
WO (1) | WO2008008433A2 (pt) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
US8309603B2 (en) * | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
US20160089356A1 (en) * | 2006-07-12 | 2016-03-31 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
US20070077310A1 (en) * | 2005-10-03 | 2007-04-05 | University Of Tennessee Research Foundation | Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species |
PT2038252T (pt) * | 2006-07-12 | 2016-12-16 | Univ Tennessee Res Found | Acilanilidos substituidos e métodos de utilização dos mesmos |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US7931380B2 (en) * | 2006-09-05 | 2011-04-26 | Williams Robert C | Imaging apparatus for providing background separated images |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
BRPI0907844B8 (pt) | 2008-02-22 | 2021-05-25 | Radius Health Inc | compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos |
WO2010056758A1 (en) * | 2008-11-12 | 2010-05-20 | Yangbo Feng | Quinazoline derivatives as kinase inhibitors |
KR20100060189A (ko) * | 2008-11-27 | 2010-06-07 | 국립암센터 | 에타크리닉 산을 포함하는 트란스글루타미나제 관련 질환 예방 또는 치료용 조성물 및 그를 이용하는 트란스글루타미나제 관련 질환 예방 또는 치료 방법 |
US8470833B2 (en) | 2009-12-15 | 2013-06-25 | Mcneil-Ppc, Inc. | Hair growth and/or regrowth compositions |
US8470880B2 (en) | 2009-12-15 | 2013-06-25 | Mcneil-Ppc, Inc. | Methods of reducing hair loss and/or facilitating hair growth and/or regrowth |
WO2011085385A1 (en) * | 2010-01-11 | 2011-07-14 | Gtx, Inc. | Methods of treating meibomian gland dysfunction |
AU2011212813B2 (en) | 2010-02-04 | 2014-10-23 | Radius Health, Inc. | Selective androgen receptor modulators |
US20130053448A1 (en) | 2010-05-12 | 2013-02-28 | Louis O'Dea | Therapeutic Regimens |
US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
CN102464610B (zh) * | 2010-11-16 | 2014-07-30 | 北大方正集团有限公司 | 一种美替拉酮的制备方法 |
CN102093248B (zh) * | 2010-12-22 | 2013-12-04 | 蚌埠丰原医药科技发展有限公司 | 一种制备盐酸丙胺卡因的方法 |
MX2014000419A (es) | 2011-07-15 | 2014-09-22 | Nusirt Sciences Inc | Composicones y metodos para modular trayectorias metabolicas. |
CN103930132A (zh) | 2011-09-27 | 2014-07-16 | 拜奥迈德瓦利探索有限公司 | 治疗胶质瘤的组合物和方法 |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
CN108143728A (zh) * | 2012-07-13 | 2018-06-12 | Gtx公司 | 选择性雄激素受体调节剂在治疗乳癌中的用途 |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
JP6401702B2 (ja) | 2012-09-07 | 2018-10-10 | ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ | 炎症性肝疾患の診断のための方法および組成物 |
CN108452311A (zh) | 2012-11-13 | 2018-08-28 | 纽斯尔特科学公司 | 用于增强能量代谢的组合物和方法 |
CN105228627B (zh) | 2013-03-15 | 2018-07-13 | 纽斯尔特科学公司 | 亮氨酸和烟酸降低脂质水平 |
EP2981258B8 (en) | 2013-04-05 | 2020-11-11 | scPharmaceuticals Inc. | Pharmaceutical formulations for subcutaneous administration of furosemide |
JP2016523918A (ja) | 2013-06-27 | 2016-08-12 | シーダーズ−サイナイ メディカル センター | 神経変性状態の予防および治療のためのアドレナリン受容体拮抗薬 |
HUE043959T2 (hu) * | 2013-12-23 | 2019-09-30 | Bcn Peptides Sa | Bikalutamid analógok vagy (S)-bikalutamid, mint exocitózist aktiváló vegyületek lizoszomális tárolási zavar vagy glikogenózis kezelésében történõ alkalmazásra |
CN103772238B (zh) * | 2014-01-24 | 2017-03-22 | 苏州伊莱特新药研发有限公司 | 一类新的含酯基芳香丙酰胺化合物及其制备方法和用途 |
RU2019107011A (ru) | 2014-01-24 | 2019-04-08 | Лэм Терапьютикс, Инк. | Композиции апилимода и способы их применения |
CN106456997B (zh) | 2014-02-27 | 2018-12-28 | 纽斯尔特科学公司 | 用于减少或预防肝性脂肪变性的组合物和方法 |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
SI3122426T1 (sl) | 2014-03-28 | 2023-04-28 | Duke University | Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev |
US10206910B2 (en) | 2014-11-07 | 2019-02-19 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
US20190209576A1 (en) | 2014-11-07 | 2019-07-11 | AI Therapeutics, Inc. | Apilimod for use in the treatment of colorectal cancer |
EP4039253A1 (en) | 2015-04-29 | 2022-08-10 | Radius Pharmaceuticals, Inc. | Methods of treating cancer |
WO2017223115A1 (en) | 2016-06-22 | 2017-12-28 | Radius Health, Inc. | Ar+ breast cancer treatment methods |
CN106748884B (zh) * | 2016-12-13 | 2021-08-20 | 山西振东制药股份有限公司 | 一种比卡鲁胺中间体的制备方法 |
WO2018109670A1 (en) | 2016-12-15 | 2018-06-21 | Nestec Sa | Compositions and methods that modulate vitamin d and bone mineral content in a companion animal |
EP3565542B1 (en) | 2017-01-05 | 2024-04-10 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
US20200046722A1 (en) * | 2017-02-28 | 2020-02-13 | India Globalization Capital, Inc. | Method and composition for treating eating disorders |
BR112020016256A2 (pt) | 2018-02-21 | 2020-12-15 | AI Therapeutics, Inc. | Terapia de combinação com apilimod e agentes gluta-matérgicos |
PL3681500T3 (pl) | 2018-04-24 | 2022-08-01 | Allergan, Inc. | Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności |
CN108451958A (zh) * | 2018-05-11 | 2018-08-28 | 胡晨波 | 熊去氧胆酸的用途 |
JP7473486B2 (ja) | 2018-07-04 | 2024-04-23 | ラジウス ファーマシューティカルズ,インコーポレイテッド | Rad1901-2hclの多形形態 |
TR2021005231A1 (tr) * | 2018-09-27 | 2022-02-21 | Univ Yildiz Teknik | Sperm hizini arttiran serotoni̇n etken maddesi̇ i̇çeren bi̇leşi̇m |
CN109761778A (zh) * | 2018-12-10 | 2019-05-17 | 石家庄市度智医药科技有限公司 | 一种合成光学活性α-羟基丙酰胺衍生物的方法 |
US11246851B2 (en) | 2019-01-04 | 2022-02-15 | Sq Innovation Ag | Pharmaceutical compositions of furosemide and uses thereof |
MX2021009084A (es) | 2019-01-31 | 2021-10-26 | Scpharmaceuticals Inc | Formulaciones farmaceuticas liquidas concentradas de furosemida y metodos para administrar las mismas. |
CN110156584B (zh) * | 2019-04-28 | 2023-04-07 | 长春金赛药业有限责任公司 | 一种(2r)-3-溴-2-羟基-2-甲基丙酸的合成方法 |
CN110917173B (zh) * | 2019-12-02 | 2020-11-10 | 北京理工大学 | 一种主动趋炎抗炎工程化外泌体及其制备方法 |
US20230047313A1 (en) * | 2019-12-16 | 2023-02-16 | Children`S Medical Center Corporation | Treating heart disease in muscular dystrophy patients |
RU2752994C1 (ru) * | 2020-11-11 | 2021-08-11 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ прогнозирования эффективности низкоинтенсивной лазерной терапии при аутоиммунном бесплодии у мужчин |
CN113402490B (zh) * | 2021-03-29 | 2023-01-03 | 白银京宇新药业有限公司 | 一种1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮的制备方法 |
WO2023287755A1 (en) * | 2021-07-12 | 2023-01-19 | Fred Mermelstein | High dose histamine h2-receptor antagonists for the treatment of hypoleptinemia and associated metabolic disorders including methods and compositions to said treatment |
CN116836438B (zh) * | 2023-07-11 | 2024-02-09 | 江西塔益莱高分子材料有限公司 | 一种pcb干膜树脂及其制备方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3239345A (en) | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
US3865801A (en) | 1973-06-15 | 1975-02-11 | Atomic Energy Commission | Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol |
US4036979A (en) | 1974-01-25 | 1977-07-19 | American Cyanamid Company | Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate |
KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
EP0400051B1 (en) | 1988-01-28 | 1995-05-10 | Polygen Holding Corporation | Polypeptide compounds having growth hormone releasing activity |
ATE113607T1 (de) | 1988-01-28 | 1994-11-15 | Polygen Holding Corp | Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität. |
US5179080A (en) | 1989-08-31 | 1993-01-12 | Clinical Homecare, Corp. | Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease |
JP2983629B2 (ja) | 1989-10-13 | 1999-11-29 | キリン―アムジエン・インコーポレイテツド | エリスロポエチンイソフォーム |
US5663146A (en) | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US6995284B2 (en) * | 2000-08-24 | 2006-02-07 | The University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
US20050038110A1 (en) * | 2000-08-24 | 2005-02-17 | Steiner Mitchell S. | Selective androgen receptor modulators and methods of use thereof |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
WO1998055153A1 (en) * | 1997-06-04 | 1998-12-10 | The University Of Tennessee Research Corporation | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
PL203771B1 (pl) | 1998-07-06 | 2009-11-30 | Bristol Myers Squibb Co | Pochodna bifenylosulfonamidu jako dualny antagonista receptorów angiotensyny i endoteliny, sposób jej wytwarzania i jej zastosowanie oraz pochodna bifenylu i pochodna benzenu |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
US6838484B2 (en) * | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
US7855229B2 (en) * | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
US7622503B2 (en) * | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
CN1617715B (zh) * | 2001-12-06 | 2010-05-12 | Gtx公司 | 用雄激素受体选择性调节剂治疗肌消耗 |
WO2003074450A2 (en) * | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
WO2004060146A2 (en) | 2002-12-30 | 2004-07-22 | Purdue Research Foundation | Method of treatment for central nervous system injury |
JP2006516286A (ja) * | 2003-01-22 | 2006-06-29 | ジーティーエックス・インコーポレイテッド | Sarmによる女性のアンドロゲン減少に関連する病気の治療 |
JP4428553B2 (ja) * | 2003-05-07 | 2010-03-10 | 日本甜菜製糖株式会社 | 家畜動物用予防及び/又は治療剤 |
CN1812824A (zh) * | 2003-06-30 | 2006-08-02 | 麦克公司 | 作为雄激素受体调节剂的17-乙酰氨基-4-氮杂甾体衍生物 |
AU2004281708B2 (en) * | 2003-10-14 | 2011-02-17 | University Of Tennessee Research Foundation | Treating bone-related disorders with selective androgen receptor modulators |
PT2038252T (pt) | 2006-07-12 | 2016-12-16 | Univ Tennessee Res Found | Acilanilidos substituidos e métodos de utilização dos mesmos |
-
2007
- 2007-07-12 PT PT77968238T patent/PT2038252T/pt unknown
- 2007-07-12 EP EP16194602.5A patent/EP3147278B1/en active Active
- 2007-07-12 BR BRPI0713179-8A patent/BRPI0713179A2/pt not_active Application Discontinuation
- 2007-07-12 AR ARP070103105A patent/AR061980A1/es unknown
- 2007-07-12 ES ES07796823.8T patent/ES2606313T3/es active Active
- 2007-07-12 LT LTEP07796823.8T patent/LT2038252T/lt unknown
- 2007-07-12 WO PCT/US2007/015895 patent/WO2008008433A2/en active Application Filing
- 2007-07-12 US US11/826,195 patent/US20080076828A1/en not_active Abandoned
- 2007-07-12 EA EA200900177A patent/EA018258B1/ru not_active IP Right Cessation
- 2007-07-12 MX MX2009000385A patent/MX2009000385A/es active IP Right Grant
- 2007-07-12 AU AU2007272950A patent/AU2007272950B2/en not_active Ceased
- 2007-07-12 CN CN2007800339004A patent/CN101516840B/zh not_active Expired - Fee Related
- 2007-07-12 ES ES16194602T patent/ES2780193T3/es active Active
- 2007-07-12 EP EP07796823.8A patent/EP2038252B1/en active Active
- 2007-07-12 EA EA201300242A patent/EA024161B1/ru not_active IP Right Cessation
- 2007-07-12 EA EA201690265A patent/EA031888B1/ru not_active IP Right Cessation
- 2007-07-12 PL PL07796823T patent/PL2038252T3/pl unknown
- 2007-07-12 KR KR1020137021396A patent/KR101460999B1/ko active IP Right Grant
- 2007-07-12 JP JP2009519526A patent/JP5215300B2/ja not_active Expired - Fee Related
- 2007-07-12 DK DK07796823.8T patent/DK2038252T3/en active
- 2007-07-12 CA CA2658394A patent/CA2658394C/en not_active Expired - Fee Related
- 2007-07-12 HU HUE07796823A patent/HUE032274T2/en unknown
- 2007-07-12 KR KR1020097002899A patent/KR101460693B1/ko active IP Right Grant
-
2009
- 2009-01-12 IL IL196462A patent/IL196462A/en active IP Right Grant
-
2013
- 2013-02-28 JP JP2013038501A patent/JP5719397B2/ja active Active
-
2015
- 2015-03-20 JP JP2015057553A patent/JP6069393B2/ja not_active Expired - Fee Related
- 2015-11-10 IL IL242537A patent/IL242537A/en active IP Right Grant
- 2015-11-10 IL IL242538A patent/IL242538A/en active IP Right Grant
-
2016
- 2016-12-26 JP JP2016251574A patent/JP6434482B2/ja not_active Expired - Fee Related
- 2016-12-30 CY CY20161101366T patent/CY1118472T1/el unknown
-
2018
- 2018-07-26 JP JP2018140123A patent/JP2018184452A/ja not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL196462A0 (en) | Substituted acylanilides and methods of use thereof | |
IL197185A0 (en) | Substituted acylanilides and methods of use thereof | |
IL196956A0 (en) | Aza-benzofuranyl compounds and methods of use | |
EP2023718A4 (en) | CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR | |
HK1147254A1 (en) | 5-anilinoimidazopyridines and methods of use 5- | |
IL189602A0 (en) | Indenoisoquinolinone analogs and methods of use thereof | |
IL198397A0 (en) | Anilinopiperazine derivatives and methods of use thereof | |
IL197060A0 (en) | Aza-benzothiophenyl compounds and methods of use | |
ZA200808017B (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
EP2191458A4 (en) | FINGER-FITTED DEVICES AND METHODS OF USE THEREOF | |
EP2076526A4 (en) | NEW SIRNA AND METHOD FOR ITS APPLICATION | |
EP2021555A4 (en) | STRUCTURAL ELEMENT AND METHODS OF USE THEREOF | |
IL193693A0 (en) | Purine compounds and methods of use thereof | |
GB0719577D0 (en) | Microimplant devices and methods of making and use thereof | |
IL206125A0 (en) | Azaindolizines and methods of use | |
EP2046129A4 (en) | HERBICIDE COMPOSITION AND METHOD OF USE | |
ZA200905741B (en) | Indenoisoquinolinone analogs and methods of use thereof | |
EP2046128A4 (en) | HERBICIDAL COMPOSITION AND METHOD FOR THEIR USE | |
EP2046116A4 (en) | HERBICIDE COMPOSITION AND METHOD OF USE | |
IL192564A0 (en) | Composition and method of use thereof | |
EP2046118A4 (en) | HERBICIDE COMPOSITION AND METHOD OF USE | |
ZA201004894B (en) | Nuctraceutical composition and methods of use | |
ZA200900896B (en) | Aza-benzofuranyl compounds and methods of use | |
ZA200901009B (en) | Aza-benzothiophenyl compounds and methods of use | |
ZA201004893B (en) | Nuctraceutical composition and methods of use |